As of 2025-10-29, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -4.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 917.68 mil USD. EYPT's TTM EBITDA according to its financial statements is -187.14 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 10.9x | 7.8x |
| Forward P/E multiples | 9.2x - 16.0x | 12.8x |
| Fair Price | (20.49) - (24.34) | (23.00) |
| Upside | -267.3% - -298.7% | -287.7% |
| Date | EV/EBITDA |
| 2025-10-28 | -4.90 |
| 2025-10-27 | -4.84 |
| 2025-10-24 | -4.79 |
| 2025-10-23 | -4.58 |
| 2025-10-22 | -4.56 |
| 2025-10-21 | -4.71 |
| 2025-10-20 | -4.81 |
| 2025-10-17 | -4.64 |
| 2025-10-16 | -4.60 |
| 2025-10-15 | -4.68 |
| 2025-10-14 | -5.30 |
| 2025-10-13 | -5.37 |
| 2025-10-10 | -5.47 |
| 2025-10-09 | -5.65 |
| 2025-10-08 | -5.61 |
| 2025-10-07 | -5.33 |
| 2025-10-06 | -5.49 |
| 2025-10-03 | -5.54 |
| 2025-10-02 | -5.44 |
| 2025-10-01 | -5.19 |
| 2025-09-30 | -5.76 |
| 2025-09-29 | -5.68 |
| 2025-09-26 | -5.62 |
| 2025-09-25 | -5.31 |
| 2025-09-24 | -5.69 |
| 2025-09-23 | -5.40 |
| 2025-09-22 | -5.38 |
| 2025-09-19 | -5.33 |
| 2025-09-18 | -5.55 |
| 2025-09-17 | -5.50 |
| 2025-09-16 | -5.49 |
| 2025-09-15 | -5.40 |
| 2025-09-12 | -5.38 |
| 2025-09-11 | -5.37 |
| 2025-09-10 | -5.46 |
| 2025-09-09 | -5.74 |
| 2025-09-08 | -5.51 |
| 2025-09-05 | -5.66 |
| 2025-09-04 | -4.74 |
| 2025-09-03 | -4.80 |
| 2025-09-02 | -4.68 |
| 2025-08-29 | -4.61 |
| 2025-08-28 | -4.62 |
| 2025-08-27 | -4.73 |
| 2025-08-26 | -4.81 |
| 2025-08-25 | -4.62 |
| 2025-08-22 | -4.72 |
| 2025-08-21 | -4.62 |
| 2025-08-20 | -4.58 |
| 2025-08-19 | -4.38 |